IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 6:56 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
IDXX 468.63 -9.21(-1.93%)
Will IDXX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IDXX
Unlocking Q2 Potential of Idexx (IDXX): Exploring Wall Street Estimates for Key Metrics
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
TMO or IDXX: Which Is the Better Value Stock Right Now?
Other News for IDXX
IDEXX Laboratories Announces Time Change for 2024 Second Quarter Financial Results Conference Call
IDEXX Releases 2023 Corporate Responsibility Report, Highlighting Progress Against Its Goals
GLOBAL BRIEFING: Stocks seen green as US election campaign continues
Lululemon downgraded, Birkenstock upgraded: Wall Street's top analyst calls
Idexx Laboratories initiated with bullish view at BTIG, here's why